Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1

/in

Miller, J., Hachmann, N. P., Collier, A. Y., Lasrado, N., Mazurek, C. R., Patio, R. C., Powers, O., Surve, N., Theiler, J., Korber, B., & Barouch, D. H. (2023). Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. The New England journal of medicine, 10.1056/NEJMc2214314. Advance online publication. https://doi.org/10.1056/NEJMc2214314

 

A genetically engineered, stem-cell-derived cellular vaccine

/in

Cooper, A., Sidaway, A., Chandrashekar, A., Latta, E., Chakraborty, K., Yu, J., McMahan, K., Giffin, V., Manickam, C., Kroll, K., Mosher, M., Reeves, R. K., Gam, R., Arthofer, E., Choudhry, M., Henley, T., & Barouch, D. H. (2022). A genetically engineered, stem-cell-derived cellular vaccine. Cell reports. Medicine, 3(12), 100843. https://doi.org/10.1016/j.xcrm.2022.100843

 

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6

/in ,

Hachmann, N. P., Miller, J., Collier, A. Y., & Barouch, D. H. (2022). Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6. The New England journal of medicine, 387(20), 1904–1906. https://doi.org/10.1056/NEJMc2212117

 

Allosteric Integrase Inhibitor Influences on HIV-1 Integration and Roles of LEDGF/p75 and HDGFL2 Host Factors

/in

Singh PK, Li W, Bedwell GJ, Fadel HJ, Poeschla EM, Engelman AN. Allosteric Integrase Inhibitor Influences on HIV-1 Integration and Roles of LEDGF/p75 and HDGFL2 Host Factors. Viruses. 2022; 14(9):1883. https://doi.org/10.3390/v14091883

High-Dose Inhaled Nitric Oxide for the Treatment of Spontaneously Breathing Pregnant Patients With Severe Coronavirus Disease 2019 Pneumonia

/in

Valsecchio C, Winterton D, Fakhr BS, Collier AY, Nozari A, Ortoleva J, Mukerji S, Gibson LE, Carroll RW, Shaefi S, Pinciroli R, La Vita C, Ackman JB, Hohmann E, Arora P, Barth WH, Kaimal A, Ichinose F, Berra L;DELivery oF iNO (DELFINO) Network Collaborators. High-Dose Inhaled Nitric Oxide for the Treatment of Spontaneously Breathing Pregnant Patients With Severe Coronavirus Disease 2019 Pneumonia. Obstet Gynecol. April 2022. Accepted

Durability of Heterologous and Homologous COVID-19 Vaccine Boost Regimens

/in

Tan CS, Collier AY,Yu J, Liu J, Chandrashekar A, McMahan KA, Jacob-Dolan C, He X, Roy V, Hauser BM, Munt JE, Mallory ML, Mattocks M, Powers JM, Meganck RM, Rowe M, Hemond R, Bondzie EA, Jaegle KH, Baric RS, Schmidt AG, Alter G, Le Gars M, Sadoff J, Barouch DH. Durability of Heterologous and Homologous COVID-19 Vaccine Boost Regimens. JAMA Network Open. June 2022. Accepted.

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5

/in

Hachmann NP, Miller J, Collier AY, Ventura JD, Yu J, Rowe M, Bondzie EA, Powers O, Surve N, Hall K, Barouch DH. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMc2206576. Epub ahead of print. PMID: 35731894.

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys

/in

Moldt B, Chandrashekar A, Borducchi EN, Nkolola JP, Stephenson H, Nagel M, Hung M, Goldsmith J, Pace CS, Carr B, Thomsen ND, Blair WS, Geleziunas R, Barouch DH. HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. PLoS Pathog. 2022 Apr 22;18(4):e1010467. doi: 10.1371/journal.ppat.1010467. Epub ahead of print. PMID: 35452496.

Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant

/in

Collier AY, Brown CM, McMahan KA, Yu J, Liu J, Jacob-Dolan C, Chandrashekar A, Tierney D, Ansel JL, Rowe M, Sellers D, Ahmad K, Aguayo R, Anioke T, Gardner S, Siamatu M, Bermudez-Rivera L, Hacker MR, Madoff LC, Barouch DH. Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. Sci Transl Med. 2022 Apr 20;14(641):eabn6150. doi: 10.1126/scitranslmed.abn6150. Epub 2022 Apr 20. PMID: 35258323; PMCID: PMC8995036.

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions

/in ,

Kaplonek P, Cizmeci D, Fischinger S, Collier AR, Suscovich T, Linde C, Broge T, Mann C, Amanat F, Dayal D, Rhee J, de St Aubin M, Nilles EJ, Musk ER, Menon AS, Saphire EO, Krammer F, Lauffenburger DA, Barouch DH, Alter G. mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Sci Transl Med. 2022 Mar 29:eabm2311. doi: 10.1126/scitranslmed.abm2311. Epub ahead of print. PMID: 35348368; PMCID: PMC8995030.